The UK and US have concluded a key bilateral deal that will guarantee zero import taxes on British pharmaceutical products entering the American market.
The Terms of the Accord
As part of the deal, the UK has pledged to raise spending on medicines through the NHS. This pledge ensures that duties on these key exports will stay at zero for a period of the next three years.
This development is in response to earlier threats to hike duties on branded drug imports, with increases discussed as high as 100%.
"This deal with the UK bolsters the global environment for new treatments and introduces long-overdue balance to transatlantic medicine commerce," an announcement said.
Trade Importance
Drugs represent one of the UK's biggest exports to the United States, which is clearly the largest market for large British pharmaceutical firms.
Statistics indicate that in the year prior to last September, the UK sold medicines totaling billions to the US. This amount made up nearly one-fifth of all goods exports in that span.
"This deal protects jobs, boosts investment and facilitates the UK to become a international leader for medical research," the Business and Trade Secretary stated.
Detailed NHS Changes
The agreement entails several specific pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it deems new therapies to be unaffordable by a quarter.
- Higher Drug Budget: There is a goal to raise total health service expenditure on medicines from 0.3 percent of the national economy to 0.6% over the next decade.
- Payback Limit: The sum manufacturers must return to the NHS to prevent overspending will be limited at 15%. Last year, rebates topped twenty percent.
Broader Context
This agreement takes place against a long-running dispute between the drug companies and the ministers over drug pricing and regulatory access.
The disagreement were exacerbated by assertions that American patients were charged significantly more for the identical medicines than patients in the Britain and the EU.
Over the last 18 months, several significant pharmaceutical investments in the UK have been halted or cancelled, while substantial funding commitments have been announced toward American operations.
A senior figure publicly accepted that the NHS had to spend more on drugs, noting that its budget allocation on drugs had decreased as a share of its resources over the last ten years.
